Roadmap

A Disciplined Path from Hypothesis to Therapeutic Platform

Erythraxis is executing a multi-phase development roadmap designed to translate a validated scientific hypothesis into a scalable platform.

Model Screen Rank Validate

Mechanistic and PK Modeling

The program begins with a rigorous foundation in mechanistic and pharmacokinetic modeling, where existing clinical data, literature, and internal intellectual property frameworks are used to define the exposure-response relationships that drive erythropoietic signaling.

This phase identifies pharmacokinetic variables such as Cmax, exposure variability, and time above biologically relevant thresholds that most strongly correlate with hematologic outcomes. Establishing these relationships early anchors downstream development in measurable, biologically relevant parameters rather than assumptions or single-mechanism theories.

PK Modulation Screening

The next phase advances into targeted pharmacokinetic modulation screening, where multiple non-limiting intervention strategies are systematically evaluated for their ability to reshape androgen exposure.

These include approaches spanning absorption control, formulation engineering, metabolic modulation, first-pass optimization, route selection, and dosing refinement. The objective is not to validate a predetermined solution, but to identify which class of intervention most effectively reduces peak exposure and variability while preserving therapeutic androgen activity.

Candidate Ranking and Optimization

Leading strategies are evaluated against defined translational criteria: magnitude of exposure shaping, impact on hematologic biomarkers, preservation of therapeutic efficacy, safety profile, drug interaction risk, and feasibility of pharmaceutical development.

This stage marks the transition from broad scientific exploration to focused product development, where the most promising approaches are refined into viable therapeutic candidates. The process remains iterative, continuously integrating new data to strengthen both the scientific model and development pathway.

Clinical Validation

The final stage centers on controlled human studies designed to confirm the exposure-response hypothesis in real-world settings. These studies capture both pharmacokinetic and biological endpoints, including detailed androgen exposure profiles alongside hematologic markers.

The objective is to demonstrate that targeted modulation of androgen pharmacokinetics can meaningfully reduce erythropoietic signaling and hematocrit elevation without compromising therapeutic benefit, while establishing the clinical and regulatory foundation for formal development.

Platform value creation

Flexible, scalable, and designed to evolve with data.

Throughout this roadmap, Erythraxis maintains a strategic focus on flexibility, scalability, and long-term value creation. The platform is designed to support multiple development pathways, including standalone pharmaceutical products, co-formulated therapies, and adjunctive treatment strategies.

By preserving a broad, outcome-driven framework, the company ensures that early-stage research does not constrain future innovation, while still progressing toward clearly defined translational milestones.